Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 17 10:49AM ET
5.28
Dollar change
-0.17
Percentage change
-3.12
%
Index- P/E- EPS (ttm)-4.17 Insider Own23.63% Shs Outstand5.16M Perf Week-4.17%
Market Cap28.46M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.12M Perf Month-15.79%
Income-21.62M PEG- EPS next Q- Inst Own2.17% Short Float0.52% Perf Quarter-30.16%
Sales0.34M P/S83.70 EPS this Y- Inst Trans-83.90% Short Ratio0.82 Perf Half Y20.00%
Book/sh-0.07 P/B- EPS next Y- ROA-46.68% Short Interest0.02M Perf Year-26.67%
Cash/sh4.88 P/C1.08 EPS next 5Y- ROE-231.11% 52W Range3.45 - 8.56 Perf YTD13.89%
Dividend Est.- P/FCF- EPS past 5Y20.93% ROI-74.41% 52W High-38.32% Beta1.65
Dividend TTM- Quick Ratio6.05 Sales past 5Y-25.35% Gross Margin18.48% 52W Low53.10% ATR (14)0.38
Dividend Ex-Date- Current Ratio6.05 EPS Y/Y TTM42.14% Oper. Margin-6647.51% RSI (14)40.47 Volatility3.13% 7.25%
Employees134 Debt/Eq- Sales Y/Y TTM93.75% Profit Margin-6339.59% Recom3.00 Target Price24.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q33.60% Payout- Rel Volume0.31 Prev Close5.45
Sales Surprise- EPS Surprise- Sales Q/Q-18.39% EarningsFeb 05 Avg Volume25.92K Price5.28
SMA20-10.57% SMA50-7.82% SMA200-1.43% Trades Volume2,009 Change-3.12%
Jun-06-24 06:45AM
May-20-24 07:00AM
May-02-24 07:00AM
Apr-08-24 07:00AM
Apr-03-24 02:52PM
07:15AM Loading…
Mar-28-24 07:15AM
Mar-27-24 07:00AM
Mar-21-24 07:00AM
Mar-19-24 04:00AM
Mar-14-24 07:00AM
Mar-11-24 07:00AM
Mar-06-24 07:00AM
Feb-28-24 07:00AM
Feb-12-24 05:20PM
Jan-23-24 02:00AM
07:00AM Loading…
Jan-08-24 07:00AM
Dec-21-23 07:00AM
Nov-13-23 07:29PM
Aug-16-23 07:00AM
Jul-13-23 02:00AM
Jul-12-23 11:17AM
Jul-11-23 02:00AM
Apr-27-23 07:00AM
Mar-13-23 08:00AM
Dec-22-22 07:00AM
Dec-15-22 04:05PM
Nov-10-22 07:00AM
Oct-31-22 08:00AM
Sep-29-22 07:00AM
Sep-06-22 07:00AM
07:00AM Loading…
Apr-07-22 07:00AM
Apr-01-22 07:00AM
Mar-31-22 07:00AM
Mar-28-22 07:00AM
Mar-23-22 07:00AM
Mar-17-22 07:00AM
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.